Leadership team reinforced for next phase in Protembis' clinical and regulatory growth trajectory Protembis GmbH, a privately-held emerging cardiovascular medical device company, announced today
(1)
Enrollment with advanced generation device for complete cerebral protection nearing halfway mark in clinical study in Germany and Poland Protembis GmbH, a privately held emerging medical device company, announced today the successful completion of 20 clinical cases in its European regulatory study of the ProtEmbo Cerebral Protection System. The ProtEmbo System is an intra-aortic filter device that deflects embolic material away from the brain during transcatheter aortic valve replacement (TAVR). The device is a low profile system which is delivered through the left radial artery, an ideal access site enabling physicians to avoid interference with TAVR equipment, typically delivered through the left femoral artery.